Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child

Journal of Craniofacial Surgery

Volumn 20, Issue SUPPL. 1, 2009, Pages 597-602

  Burrows, Patricia E ^a,c   Mulliken, John B ^b   Fishman, Steven J ^b   Klement, Giannoula L ^b   Folkman, Judah ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Arteriovenous malformation; Embolization; Marimastat; Matrix metalloproteinase inhibitor

Indexed keywords

ALCOHOL; DOXYCYCLINE; ENBUCRILATE; IBUPROFEN; MARIMASTAT; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADOLESCENT; ANALGESIA; ARM; ARTERIOVENOUS FISTULA; ARTERIOVENOUS MALFORMATION; ARTERIOVENOUS SHUNT; ARTICLE; ARTIFICIAL EMBOLISM; BONE DESTRUCTION; BRACHIAL ANGIOGRAPHY; CASE REPORT; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HEALING; HUMAN; HUMERUS; HUMERUS FRACTURE; IRRITABILITY; JOINT FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PAIN; PRIORITY JOURNAL; RADIOGRAPHY; RADIUS; RECURRENT DISEASE; SOFT TISSUE; SWELLING; TREATMENT DURATION; ULNA;

ANGIOGENESIS INHIBITORS; ARTERIOVENOUS MALFORMATIONS; BONES OF UPPER EXTREMITY; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS;

EID: 68249097315     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/SCS.0b013e3181927f1e     Document Type: Article

References (54)

1. Enjolras O. Malformations vasculaires complexes systematisees. Rev Prat 1992;42:2048-2052
2. Mendel T, Louis DS. Major vascular malformations of the upper extremity: long-term observation. J Hand Surg Am 1997;22:302-306
3. Blaisdell FW, Stein M. Natural history of congenital arteriovenous fistula. Cardiovasc Surg 1998;6:566-568
4. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306
5. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999;103: 1237-1241
6. Dolgilevich SM, Siri FM, Atlas SA, et al. Changes in collagenase and collagen gene expression after induction of aortocaval fistula in rats. Am J Physiol Heart Circ Physiol 2001;281:H207-H214
7. Rosenberg GA. Growth and bleeding in BAVM: another role for MMPs. Stroke 2003;34:925-931
8. Hashimoto T, Wen G, Lawton MT, et al. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke 2003;34:925-931
9. Sho E, Sho M, Singh TM, et al. Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol 2002;73:142-153
10. Malan E, Puglionisi A. Congenital angiodysplasias of the extremities. (Note II. Generalities and classification; venous dysplasias). J Cardiovasc Surg 1964;5:87-130
11. Malan E, Puglionisi A. Congenital angiodysplasias of the extremities (Note II. Arterial, arterial and venous, and haemolymphatic dysplasias). J Cardiovasc Surg 1965;6:255-345
12. Dickey KW, Pollak JS, Meier GH III, et al. Management of large high-flow arteriovenous malformations of the shoulder and upper extremity with transcatheter embolotherapy. J Vasc Interv Radiol 1995;6:765-773
13. Carr MM, Mahoney JL, Bowen CV. Extremity arteriovenous malformations: review of a series. Can J Surg 1994;37:293-299
14. Vikkula M, Boon LM, Mulliken JB. Molecular genetics of vascular malformations. Matrix Biol 2001;20:327-335
15. Wang QK. Update on the molecular genetics of vascular anomalies. Lymphat Res Biol 2005;3:226-233
16. van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res 2003;58:20-31
17. Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F, et al. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum Mol Genet 2007;16:1515-1533
18. Thomas B, Eyries M, Montagne K, et al. Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia. Eur J Clin Invest 2007;37:580-588
19. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000;26:328-331
20. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-1537
21. Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005;15:265-269
22. Revencu N, Boon LM, Mulliken JB, et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008;29: 959-965
23. Brouillard P, Vikkula M. Genetic causes of vascular malformations. Human Molecular Genetics 2007;16:R140-149
24. Zhou XP, Marsh DJ, Hampel H, et al. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000;9:765-768
25. Tan WH, Baris HN, Burrows PE, et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007;44:594-602
26. Caux F, Plauchu H, Chibon F, et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet 2007;15:767-773
27. Srinivasa RN, Burrows PE. Dural arteriovenous malformation in a child with Bannayan-Riley-Ruvalcaba syndrome. AJNR Am J Neuroradiol 2006;27:1927-1929
28. Akiyama Y, Ikeda J, Ibayashi Y, et al. Lhermitte-Duclos disease with cervical paraspinal arteriovenous fistula. Neurol Med Chir (Tokyo) 2006;46:446-449
29. Erkek E, Hizel S, Sanly C, et al. Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome. J Am Acad Dermatol 2005;53:639-643
30. Turnbull MM, Humeniuk V, Stein B, et al. Arteriovenous malformations in Cowden syndrome J Med Genet 2005;42:e50
31. Sonstein WJ, Kader A, Michelsen WJ, et al. Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study. J Neurosurg 1996; 85:838-845
32. Wautier MP, Boval B, Chappey O, et al. Cultured endothelial cells from human arteriovenous malformations have defective growth regulation. Blood 1999;94:2020-2028
33. Dawson P, Kennedy A, Petty RG. Absence of an angiogenic factor in large systemic arteriovenous malformations. Invest Radiol 1993;28: 594-597
34. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-246
35. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998;273:3604-3610
36. Gomes AS. Embolization therapy of congenital arteriovenous malformations: use of alternate approaches. Radiology 1994;190: 191-198
37. Yakes WF, Luethke JM, Merland JJ, et al. Ethanol embolization of arteriovenous fistulas: a primary mode of therapy. J Vasc Interv Radiol 1990;1:89-96
38. Pollak JS, White RI Jr. The use of cyanoacrylate adhesives in peripheral embolization. J Vasc Interv Radiol 2001;12:907-913
39. Jackson JE, Mansfield AO, Allison DJ. Treatment of high-flow vascular malformations by venous embolization aided by flow occlusion techniques. Cardiovasc Intervent Radiol 1996;19:323-328
40. Gomes AS, Mali WP, Oppenheim WL. Embolization therapy in the management of congenital arteriovenous malformations. Radiology 1982;144:41-49
41. Rockman CB, Rosen RJ, Jacobowitz GR, et al. Transcatheter embolization of extremity vascular malformations: the long-term success of multiple interventions. Ann Vasc Surg 2003;17:417-423
42. Stanley RJ, Cubillo E. Nonsurgical treatment of arteriovenous malformations of the trunk and limb by transcatheter arterial embolization. Radiology 1975;115:609-612
43. Shultz RE, Richardson DD, Kempf KK, et al. Treatment of a central arteriovenous malformation of the mandible with cyanoacrylate: a 4-year follow-up. Oral Surg Oral Med Oral Pathol 1988;65:267-271
44. Tan KT, Simons ME, Rajan DK, et al. Peripheral high-flow arteriovenous vascular malformations: a single-center experience. J Vasc Interv Radiol 2004;15:1071-1080
45. Siu WW, Weill A, Gariepy JL, et al. Arteriovenous malformation of the mandible: embolization and direct injection therapy. J Vasc Interv Radiol 2001;12:1095-1098
46. Beek FJ, ten Broek FW, van Schaik JP, et al. Transvenous embolisation of an arteriovenous malformation of the mandible via a femoral approach. Pediatr Radiol 1997;27:855-857
47. Do YS, Yakes WF, Shin SW, et al. Ethanol embolization of arteriovenous malformations: interim results. Radiology 2005;235: 674-682
48. Kheradmand F, Werner E, Tremble P, et al. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998;280:898-902
49. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75
50. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494
51. Gaetani P, Rodriguez y Baena R, Tartara F, et al. Metalloproteases and intracranial vascular lesions. Neurol Res 1999;21:385-390
52. Marler JJ, Fishman SJ, Kilroy SM, et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 2005;116:38-45
53. Abbruzzese TA, Guzman RJ, Martin RL, et al. Matrix metalloproteinase inhibition limits arterial enlargements in a rodent arteriovenous fistula model. Surgery 1998;124:328-334; discussion 334-325
54. Miller KD, Gradishar W, Schuchter L, et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 2002;13:1220-1224